Novanta Inc. reported second quarter fiscal 2026 financial results on August 5, 2026, for the period ended July 3, 2026. GAAP revenue increased 10% to $266 million, driven by a 9.3% organic growth rate. GAAP net income rose to $13 million, with diluted EPS of $0.30 compared to $0.12 in the prior year period. Adjusted EBITDA grew 16% to $61 million, and adjusted diluted EPS increased 17% to $0.89. The company raised its full-year 2026 GAAP revenue guidance to a range of $1,130 million to $1,140 million, reflecting the expected contribution from the recently closed acquisition of Riverpoint Medical. Novanta Inc. operates in the advanced technology and medical equipment sectors, providing core technology solutions for precision medicine, manufacturing, and surgery.
